Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B8c7fc7f1eaebeb2de1877efb7e0ff55d> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B8c7fc7f1eaebeb2de1877efb7e0ff55d NCIT_P378 "CDISC-GLOSS" @default.
- B8c7fc7f1eaebeb2de1877efb7e0ff55d type Axiom @default.
- B8c7fc7f1eaebeb2de1877efb7e0ff55d annotatedProperty NCIT_P325 @default.
- B8c7fc7f1eaebeb2de1877efb7e0ff55d annotatedSource NCIT_C71724 @default.
- B8c7fc7f1eaebeb2de1877efb7e0ff55d annotatedTarget "A potential pathway for a patient with an immediately life-threatening condition or serious disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available. NOTE: The intent is treatment, as opposed to research. Individual, Intermediate-size, and Widespread Use Expanded Access, also Emergency IND, are all programs administered under FDA guidelines. Additionally, the US Right-to-Try Act, which is independent of FDA, expands access. [FDA Expanded Access: Information for Physicians]" @default.